TPST Stock Slides As Dilutive Financing Overhang Builds

Tempest Therapeutics Inc. faces intense pressure as critical clinical trial concerns emerge, and stocks have been trading down by -11.57 percent

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TPST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Existing Tempest Therapeutics holders registered up to 8.91M shares for resale, adding a clear supply overhang with no cash going to the company.
A discounted $7.5M Tempest Therapeutics private placement at $0.805 per share, with Series C and D warrants, brings meaningful dilution pressure to TPST.
A $2.5M upfront TPST private placement, plus roughly $5M more potential from warrant exercises, is earmarked to fund working capital and the in vivo CAR-T pipeline.

Live Update At 09:17:26 EDT: On Thursday, September 17, 2026 Tempest Therapeutics Inc. stock [NASDAQ: TPST] is trending down by -11.57%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TPST has been trading like a classic micro-cap biotech under stress. Over the last few weeks, Tempest Therapeutics has drifted from the low $1s toward sub-$1 levels, then snapped back to close around $1.21 on 2026/09/16 after a high of $1.48. That’s a big intraday range for a dollar stock, which tells traders one thing: volatility is alive and well in TPST.

Zoom in to the intraday tape and Tempest Therapeutics shows a narrow band between roughly $1.03 and $1.12, with lots of tiny candles and fading volume. This kind of choppy, low-dollar action often means day traders are in control while bigger money waits on the sidelines.

More Breaking News

Fundamentally, the numbers behind TPST are rough. Tempest Therapeutics posted a quarterly net loss of about $5.24M and negative operating cash flow of roughly $2.78M as of 2026/06/30, with only $1.22M in cash left. The balance sheet shows negative equity and a current ratio of 0.4, signaling real funding pressure. For short-term traders, that combination usually translates to one word: dilution. And that’s exactly what TPST just delivered.

Why Traders Are Watching TPST’s Dilution Wave

Tempest Therapeutics is in the middle of a financing pivot that every small-cap biotech trader needs to study. On 2026/08/21, existing TPST shareholders filed to sell up to 8.91M shares of common stock. TPST itself will not receive a single dollar from those resales. For traders, that is classic overhang — a big block of potential supply sitting above the market, ready to weigh on any bounce.

Then Tempest Therapeutics followed with a discounted private placement. TPST is raising about $7.5M by selling common shares plus long-dated Series C warrants and shorter-dated Series D warrants, all effectively priced at $0.805 per share. When a company like Tempest Therapeutics sells stock at a discount to where TPST has been trading, the market usually gravitates toward that financing level. It becomes a magnet for price, and often a ceiling in the short term.

On top of that, TPST structured the deal so that only $2.5M comes in upfront. The rest — roughly $5M — depends on whether traders exercise those Series C and D warrants at the same $0.805 level. Tempest Therapeutics is tying this capital to its in vivo CAR-T pipeline and general corporate purposes, which is the long-term story. But for active traders, the near-term story in TPST is simple: more shares, more warrants, more pressure.

This is why TPST keeps popping on volume spikes and then fading. Every push higher in Tempest Therapeutics meets traders who know there is cheap stock and warrant supply in the background. Understanding that dynamic is how disciplined traders stay one step ahead on TPST.

Conclusion

TPST is a textbook case of a cash-hungry micro-cap biotech trying to keep its programs alive while the market demands a discount. Tempest Therapeutics has negative equity, weak liquidity, and steady cash burn. The company responded with a discounted $7.5M private placement at $0.805, layered with Series C and D warrants, while existing holders registered up to 8.91M shares for resale. Together, those moves put serious supply overhang on TPST in the near term.

That does not mean Tempest Therapeutics is untradeable. It just means TPST is now a pure sentiment and liquidity game. Sharp traders will watch the $0.80 area closely as a key reference — it’s the effective financing price, the warrant strike, and likely the battleground where Tempest Therapeutics either finds support or cracks lower.

For those who study charts, filings, and dilution risk, TPST offers a clear real-time case study. As Tim Sykes likes to say, “The market rewards prepared traders, not hopeful ones.” As Tim Bohen, lead trainer with StocksToTrade says, “There’s a pattern in everything; you just have to stick around long enough to see it.” Tempest Therapeutics is handing the market a very clear story: heavy dilution, high volatility, and plenty of teaching value for anyone willing to do the work. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!